Alpha 2.0
Login Register
» Authors » Lisa E Blumencranz

Lisa E Blumencranz

Explore the profile of Lisa E Blumencranz including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 6
Citations 20
Followers 0
Related Specialties
Oncology
General Surgery
Top 10 Co-Authors
William Audeh
Andrea R Menicucci
Erin B Yoder
Laura A Lee
Paul L Baron
James V Pellicane
Peter D Beitsch
Andrew Y Ashikari
Christine Finn
Mary K Murray
Published In
Ann Surg Oncol
JCO Precis Oncol
Surg Oncol Clin N Am
Surg Oncol
Affiliations
Soon will be listed here.
Recent Articles
1.
The Predictive Utility of MammaPrint and BluePrint in Identifying Patients with Locally Advanced Breast Cancer Who are Most Likely to Have Nodal Downstaging and a Pathologic Complete Response After Neoadjuvant Chemotherapy
Blumencranz P, Habibi M, Shivers S, Acs G, Blumencranz L, Yoder E, et al.
Ann Surg Oncol . 2023 Sep; 30(13):8353-8361. PMID: 37658272
Background: Neoadjuvant chemotherapy (NCT) increases the feasibility of surgical resection by downstaging large primary breast tumors and nodal involvement, which may result in surgical de-escalation and improved outcomes. This subanalysis...
2.
Combined 70- and 80-gene signatures identify tumors with genomically luminal biology responsive to neoadjuvant endocrine therapy and are prognostic of 5-year outcome in early-stage breast cancer
Pellicane J, Beitsch P, Rock D, Budway R, Dul C, Kelemen P, et al.
Surg Oncol . 2022 Nov; 45:101885. PMID: 36436423
Background: As more patients with early-stage breast cancer receive neoadjuvant endocrine therapy (NET), there is a need for reliable biomarkers that can identify patients with HR+ HER2- tumors who are...
3.
Genomic Classification of HER2-Positive Patients With 80-Gene and 70-Gene Signatures Identifies Diversity in Clinical Outcomes With HER2-Targeted Neoadjuvant Therapy
Whitworth P, Beitsch P, Murray M, Richards P, Mislowsky A, Dul C, et al.
JCO Precis Oncol . 2022 Sep; 6:e2200197. PMID: 36108259
Purpose: The prospective Neoadjuvant Breast Registry Symphony Trial compared the 80-gene molecular subtyping signature with clinical assessment by immunohistochemistry and/or fluorescence in situ hybridization in predicting pathologic complete response (pCR)...
4.
Distinct Neoadjuvant Chemotherapy Response and 5-Year Outcome in Patients With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Tumors That Reclassify as Basal-Type by the 80-Gene Signature
Whitworth P, Beitsch P, Pellicane J, Baron P, Lee L, Dul C, et al.
JCO Precis Oncol . 2022 Apr; 6:e2100463. PMID: 35476550
Purpose: The 80-gene molecular subtyping signature (80-GS) reclassifies a proportion of immunohistochemistry (IHC)-defined luminal breast cancers (estrogen receptor-positive [ER+], human epidermal growth factor receptor 2-negative [HER2-]) as Basal-Type. We report...
5.
Age-Independent Preoperative Chemosensitivity and 5-Year Outcome Determined by Combined 70- and 80-Gene Signature in a Prospective Trial in Early-Stage Breast Cancer
Whitworth P, Beitsch P, Pellicane J, Baron P, Lee L, Dul C, et al.
Ann Surg Oncol . 2022 Apr; PMID: 35378634
Background: The Neoadjuvant Breast Symphony Trial (NBRST) demonstrated the 70-gene risk of distant recurrence signature, MammaPrint, and the 80-gene molecular subtyping signature, BluePrint, precisely determined preoperative pathological complete response (pCR)...
6.
Molecular analysis of breast sentinel lymph nodes
Blumencranz P, Pieretti M, Allen K, Blumencranz L
Surg Oncol Clin N Am . 2011 Jun; 20(3):467-85, viii. PMID: 21640916
Lymphatic mapping and sentinel lymph node (SLN) biopsy have become the standard of care for staging the axilla in patients with invasive breast cancer. Current histologic methods for SLN evaluation...